Solventum (SOLV) Q1 2025 earnings summary

Executive summary

• Q1 FY25 net sales reached $2,070 million, up 2.6% year-over-year, with 4.3% organic growth led by MedSurg and Health Information Systems segments.

• Adjusted EPS was $1.34, exceeding expectations, while GAAP EPS was $0.78; net income declined to $137 million due to higher standalone and transition costs.

• Raised full-year organic sales growth outlook to 1.5%-2.5% (2.0%-3.0% excluding SKU exits), with adjusted EPS guidance unchanged at $5.45-$5.65.

• Announced sale of Purification & Filtration business for $4.1 billion, expected to close by end of 2025.

• Transformation and separation milestones advanced, with ongoing restructuring and operational enhancements.

Financial highlights

• Q1 net sales: $2,070 million (+2.6% reported, +4.3% organic); MedSurg and Health Information Systems drove growth.

• Adjusted operating income: $407 million (margin 19.7%); GAAP operating margin: 7.3%.

• Gross margin: 53.8%-55.6%, down year-over-year due to higher supply and transition costs.

• Net income: $137 million, down from $237 million year-over-year.

• Free cash flow: $(80) million, reflecting planned payments and separation costs.

Outlook and guidance

• Full-year organic sales growth outlook raised to 1.5%-2.5% (2.0%-3.0% excluding SKU exits); adjusted EPS guidance maintained at $5.45-$5.65.

• Free cash flow guidance unchanged at $450-$550 million.

• Tariff headwinds of $80-$100 million expected in 2025, mainly in the second half, with EPS impact of $0.35-$0.45.

• FX impact now neutral to reported sales growth; prior assumption was a headwind.

• Guidance includes Purification & Filtration segment; update to follow post-sale.